Literature DB >> 4040770

Platelet-associated complement in chronic ITP.

Y Kurata, J G Curd, J D Tamerius, R McMillan.   

Abstract

Chronic ITP is due to antibody-induced destruction of platelets by the reticuloendothelial (RE) system. The role of complement in this process is unclear. We measured platelet-associated complement (PAC) components C3, C3bi, C4 and C9 in 16 patients with chronic ITP, in two of these patients prior to and after splenectomy. Competitive solid-phase radioimmunoassays using monoclonal antibody (anti-C3d, anti-C3bi neoantigen or anti-C9) or affinity-purified heterologous antibody (anti-C4) were used. Mean values (+/- SD) of normal subjects (ng/10(7) plts) were: PAC3d 17.6 +/- 6.8; PAC3bi 11.6 +/- 2.3; PAC4 1.6 +/- 0.5; PAC9 9.9 +/- 2.6. Significantly elevated (greater than 2 SD) PAC3, PAC3bi, PAC4 and PAC9 levels occurred in 12/16, 11/14, 10/14 and 5/9 chronic ITP patients. The PAC3, PAC3bi and PAC9 values correlated inversely with the patients' platelet counts (P less than 0.001); PAC4 levels did not. A positive correlation was also noted between PAC3, PAC3bi and PAC9 while PAC4 values showed no correlation. Two patients with preoperative elevation of all four PAC proteins showed normalization of PAC3, PAC3bi and PAC9 values after a splenectomy-induced remission; PAC4 levels remained elevated for up to 5 months after surgery. We conclude that in vivo C activation occurs in most chronic ITP patients with binding of C3 and C9 to the platelet surface. This in vivo C activation may promote more efficient phagocytosis (C3b) and possibly platelet lysis (C5-9) in some ITP patients.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4040770     DOI: 10.1111/j.1365-2141.1985.tb07477.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  6 in total

1.  In vitro fixation of C3d and C5b-9 on platelets by human platelet reactive antibodies.

Authors:  V Kiefel; A Salama; C Mueller-Eckhardt
Journal:  Blut       Date:  1989-01

2.  Study of platelet-associated immunoglobulins of IgG, IgM, IgA, and IgE classes and platelet kinetics in 33 patients with idiopathic thrombocytopenic purpura.

Authors:  M R Movahed Shariat Panahi; S Le Blanc; O Schober; R Coldewey; H Deicher
Journal:  Ann Hematol       Date:  1994-09       Impact factor: 3.673

3.  Potential risk factors for the development from immune thrombocytopenia to systemic lupus erythematosus: a case-control study in Chinese children.

Authors:  Yuqing Song; Yuelun Zhang; Zhuo Li; Jing Liu; Juan Xiao; Hongmei Song
Journal:  Ann Hematol       Date:  2022-05-09       Impact factor: 3.673

4.  Serum complement levels in immune thrombocytopenia: Characterization and relation to clinical features.

Authors:  Abraham Z Cheloff; David J Kuter; Hanny Al-Samkari
Journal:  Res Pract Thromb Haemost       Date:  2020-06-21

5.  Regulation of the activity of platelet-bound C3 convertase of the alternative pathway of complement by platelet factor H.

Authors:  D V Devine; W F Rosse
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

Review 6.  Immune Thrombocytopenia: Recent Advances in Pathogenesis and Treatments.

Authors:  Sylvain Audia; Matthieu Mahévas; Martin Nivet; Sethi Ouandji; Marion Ciudad; Bernard Bonnotte
Journal:  Hemasphere       Date:  2021-06-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.